| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Novartis AG | TOUR006 - (TRANQUILITY) | Atherosclerotic cardiovascular disease (ASCVD) | Phase 3 | Trial Planned | Intravenous | Cardiology |
| Novartis AG | Leqvio - (V-INITIATE) | Low-density lipoprotein cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease (ASCVD) | Phase 3 | Data Released | Subcutaneous | Cardiology |
| Novartis AG | Zolgensma (onasemnogene abeparvovec) - (SMART) | Spinal muscular atrophy (SMA) | Phase 3 | Data Released | Intravenous infusion | Genetic Disorder |
| Novartis AG | Ianalumab - (NEPTUNUS-2) | Sjögren’s syndrome | Phase 3 | Data Released | Subcutaneous | Immunology |
| Novartis AG | Cosentyx - (REPLENISH) | Polymyalgia rheumatica | Phase 3 | Data Released | Subcutaneous | #N/A |
| Novartis AG | Leqvio - (V-Mono) | CVRR (Primary prevention) | Phase 3 | Data Released | Subcutaneous | Cardiology |
| Novartis AG | Leqvio - (ORION-13) | Hyperlipidemia (pediatrics) | Phase 3 | Ongoing | Subcutaneous | Cardiology |
| Novartis AG | Leqvio - (ORION-16) | Hyperlipidemia (pediatrics) | Phase 3 | Ongoing | Subcutaneous | Cardiology |